Chen Nanxiang, Ba Wei, Zhao Dawei, Sheng Lei, Zhang Xinxin
College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, National Clinical Research Center for Otolaryngologic Diseases, State Key Lab of Hearing Science, Ministry of Education, Beijing Key Lab of Hearing Impairment Prevention and Treatment, Beijing, China.
Department of Pathology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China.
Front Oncol. 2022 Mar 1;12:816903. doi: 10.3389/fonc.2022.816903. eCollection 2022.
Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS.
滤泡性树突状细胞肉瘤（FDCS）是一种罕见的恶性肿瘤，在世界卫生组织（WHO）2016年修订版中被归类于组织细胞和树突状细胞肿瘤。鉴于该肿瘤的罕见性，尚无标准化治疗方法。通常采用完整手术切除进行治疗。辅助化疗和放疗是替代方法。以程序性死亡受体1/程序性死亡配体1（PD-1/PD-L1）抗体为代表的免疫检查点抑制剂（ICIs）在多种实体瘤中已取得显著临床疗效。然而，关于ICIs治疗FDCS的报道很少。FDCS通常高表达PD-L1，这为FDCS病例中使用免疫疗法提供了理论依据。在此，我们报告一名51岁的菲律宾华裔男性FDCS患者，接受了包括PD-1抑制剂帕博利珠单抗在内的多模式治疗，并实现了24个月相对较长的无病生存期。该病例强调，在NGS技术指导下应用ICIs似乎是FDCS患者一种有意义的治疗选择。
